Ones To Watch News
Refine Search
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Biotechnology
Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024
Biotechnology
Swiss pharma giant Novartis has entered an agreement to acquire Dutch firm Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies. 8 January 2024
Biotechnology
Two Finnish companies, Orion Corporation and Glykos Finland Oy, have entered into a research collaboration and licensing agreement related to the development of antibody-drug conjugates (ADCs) to treat solid tumors. 8 January 2024
Pharmaceutical
Paris, France-based cardiology specialist Corteria Pharmaceuticals has announced the appointment of Dr Mark Pruzanski, as chairman of its board of directors. 6 January 2024
Biotechnology
Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024
Biotechnology
Swiss pharma giant Roche has entered into a third licensing deal this week alone, signing an agreement with Cambridge, USA-based biotech MOMA Therapeutics. 5 January 2024
Biotechnology
China and USA-based Allorion Therapeutics has announced a second licensing deal within a few days, this time entering an exclusive agreement with US clinical-state biotech Avenzo Therapeutics. 5 January 2024
Biotechnology
US pharma major AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVec platform. 5 January 2024
Biotechnology
French rare disease company Innate Pharma has received good news from the US Food and Drug Administration, with a partial clinical hold being lifted from its lacutamab program. 5 January 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma yesterday provided an update on its clinical development programs and outlined its strategic priorities for 2024. 5 January 2024
Biotechnology
Californian rare disease company Ultragenyx Pharmaceutical has received a positive reimbursement decision from the UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE). 5 January 2024
Biotechnology
Boston, USA-based biotech start-up Kojin Therapeutics has announced the appointment of Harvey Berger as its new chairman, president and chief executive (CEO). 5 January 2024
Pharmaceutical
Germany’s Merck KGaA has announced a licensing agreement with New York-based small molecule developer Inspirna. 4 January 2024
Biotechnology
A significant collaboration agreement has been reached between Belgian biotech Galapagos and private Californian company BridGene Biosciences. 4 January 2024
Pharmaceutical
US pharma company Esperion Therapeutics on Wednesday announced a $125 million deal with Japanese drugmaker Daiichi Sankyo’s European subsidiary (DSE) to resolve Esperion's demand for $300 million from the company over Esperion's cholesterol reduction drugs. 4 January 2024
Biotechnology
US clinical-stage biotech start-up QurAlis has announced the opening of its European Union (EU) headquarters in Leiden, the Netherlands. 4 January 2024
Biotechnology
French immuno-oncology company Innate Pharma today announced that it has strengthened its leadership and corporate governance with the appointment of two new executive board members. 4 January 2024
Biotechnology
Adding to the growing list pf big pharma licensing and M&A deals in the attractive area of antibody-drug conjugate (ADC) drugs, China-headquartered MediLink Therapeutics has entered into a worldwide collaboration and license accord with Swiss pharma giant Roche. 3 January 2024
Biotechnology
US clinical-stage biotech Remix Therapeutics today announced a collaboration and license agreement with Swiss pharma giant Roche. 3 January 2024
Biotechnology
US clinical-stage immunotherapy specialist ImmunityBio yesterday announced an up to $320 million royalty financing and equity investment in the company by Oberland Capital. 3 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze